BRNS vs. GBIO, XBIT, STTK, GTHX, MCRB, ABOS, VTYX, OTLK, INBX, and CADL
Should you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include Generation Bio (GBIO), XBiotech (XBIT), Shattuck Labs (STTK), G1 Therapeutics (GTHX), Seres Therapeutics (MCRB), Acumen Pharmaceuticals (ABOS), Ventyx Biosciences (VTYX), Outlook Therapeutics (OTLK), Inhibrx (INBX), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry.
Generation Bio (NASDAQ:GBIO) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings.
In the previous week, Generation Bio and Generation Bio both had 4 articles in the media. Barinthus Biotherapeutics' average media sentiment score of 0.74 beat Generation Bio's score of 0.70 indicating that Generation Bio is being referred to more favorably in the media.
Barinthus Biotherapeutics has lower revenue, but higher earnings than Generation Bio. Generation Bio is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Barinthus Biotherapeutics has a net margin of 0.00% compared to Barinthus Biotherapeutics' net margin of -1,696.87%. Generation Bio's return on equity of -36.61% beat Barinthus Biotherapeutics' return on equity.
95.2% of Generation Bio shares are owned by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. 21.1% of Generation Bio shares are owned by insiders. Comparatively, 8.0% of Barinthus Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Generation Bio has a beta of 2.83, indicating that its stock price is 183% more volatile than the S&P 500. Comparatively, Barinthus Biotherapeutics has a beta of -0.52, indicating that its stock price is 152% less volatile than the S&P 500.
Generation Bio presently has a consensus price target of $8.00, indicating a potential upside of 127.92%. Barinthus Biotherapeutics has a consensus price target of $5.50, indicating a potential upside of 301.46%. Given Generation Bio's stronger consensus rating and higher possible upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than Generation Bio.
Generation Bio received 29 more outperform votes than Barinthus Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Barinthus Biotherapeutics an outperform vote while only 67.86% of users gave Generation Bio an outperform vote.
Summary
Barinthus Biotherapeutics beats Generation Bio on 11 of the 17 factors compared between the two stocks.
Get Barinthus Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Barinthus Biotherapeutics Competitors List
Related Companies and Tools
